# US 2020/0390891 A1 · Polymer-based sustained release device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390891 A1
- Document ID: US20200390891A1
- Status: Published application
- Kind: A1
- Application number: 16/749,584
- Filed: 2020-01-22
- Published: 2020-12-17
- Earliest claimed: 2004-04-15
- Assignees: Alkermes Pharma Ireland Limited
- Applicants: Alkermes Pharma Ireland Limited
- Inventors: Steven G. Wright; Troy Christensen; Thean Yeoh; Michael E. Rickey; Joyce M. Hotz; Rajesh Kumar; Henry R. Costantino
- Web page: https://patentgrep.com/patent/US20200390891A1

## CPC

- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 38/2278: {Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)}
- A61K 38/26: Glucagons
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 47/38: Cellulose; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.

## Claims

### Claim 1

An injectable composition for sustained release of a glucoregulatory polypeptide, comprising:
a biocompatible polymer having the glucoregulatory polypeptide dispersed therein so as to be present at about 3 to 10% (w/w) of the weight of the composition, and a sugar dispersed therein so as to be present at about 0.1 to 5% (w/w) of the weight of the composition,
wherein the injectable composition is free from additional ingredients that alter the rate of release of the glucoregulatory polypeptide from the injectable composition, and
wherein sustained release of the glucoregulatory polypeptide occurs over at least a period of about one week.

### Claim 2 (depends on 1)

The injectable composition of claim 1, wherein the sustained release of the glucoregulatory polypeptide occurs over at least a period of about two weeks.

### Claim 3 (depends on 1)

The injectable composition of claim 1, wherein the sustained release of the glucoregulatory polypeptide occurs over at least a period of about three weeks.

### Claim 4 (depends on 1)

The injectable composition of claim 1, wherein the sustained release of the glucoregulatory polypeptide occurs over at least a period of about four weeks.

### Claim 5 (depends on 1)

The injectable composition of claim 1, wherein the glucoregulatory polypeptide is exendin-4.

### Claim 6 (depends on 2)

The injectable composition of claim 2, wherein the glucoregulatory polypeptide is exendin-4.

### Claim 7 (depends on 3)

The injectable composition of claim 3, wherein the glucoregulatory polypeptide is exendin-4.

### Claim 8 (depends on 4)

The injectable composition of claim 4, wherein the glucoregulatory polypeptide is exendin-4.

### Claim 9 (depends on 1)

A method of treating a patient suffering from Type 2 diabetes, comprising administering a therapeutically effective amount of the injectable composition of claim 1.

### Claim 10 (depends on 9)

The method of claim 9, wherein the glucoregulatory polypeptide is exendin-4.
